(Q37738362)

22 August 2017

1 reference

title

Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia (English)

1 reference

22 August 2017

1 reference

Tiffany Thomas

1

1 reference

22 August 2017

Henry Ginsberg

series ordinal

2

1 reference

22 August 2017

publication date

1 January 2010

1 reference

Current Atherosclerosis Reports

22 August 2017

published in

1 reference

22 August 2017

volume

12

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

58-65

1 reference

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0078-7

Recent progress in understanding apolipoprotein B.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0078-7

2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0078-7

Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases

21 January 2018

1 reference

12 December 2020

APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation

1 reference

12 December 2020

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

1 reference

12 December 2020

Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes

1 reference

12 December 2020

Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol

1 reference

12 December 2020

Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety

1 reference

12 December 2020

Progress in antisense technology.

1 reference

12 December 2020

Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.

1 reference

12 December 2020

Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix

1 reference

12 December 2020

Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid

1 reference

12 December 2020

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

1 reference

12 December 2020

Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies

1 reference

12 December 2020

Antisense oligonucleotides as therapeutics for hyperlipidaemias

1 reference

12 December 2020

Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice

1 reference

12 December 2020

RNAi-mediated gene silencing in non-human primates.

1 reference

12 December 2020

Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations

1 reference

12 December 2020

Progress in antisense technology: the end of the beginning

1 reference

12 December 2020

Statin safety: a systematic review

1 reference

12 December 2020

Antisense technologies. Improvement through novel chemical modifications

1 reference

12 December 2020

Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity

1 reference

12 December 2020

Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia

1 reference

12 December 2020

Management of the statin-intolerant patient

1 reference

12 December 2020

The role of the microsomal triglygeride transfer protein in abetalipoproteinemia

1 reference

12 December 2020

Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48

1 reference

12 December 2020

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

1 reference

12 December 2020

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

1 reference

12 December 2020

Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.

1 reference

12 December 2020

Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes.

1 reference

12 December 2020

Familial hypobetalipoproteinemia.

1 reference

12 December 2020

Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.

1 reference

12 December 2020

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

1 reference

12 December 2020

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

1 reference

12 December 2020

Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB

1 reference

12 December 2020

Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease

1 reference

12 December 2020

Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis.

1 reference

12 December 2020

Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation

1 reference

12 December 2020

10.1007/S11883-009-0078-7

Identifiers

DOI

1 reference

22 August 2017

1 reference